Index S&P 500
P/E 42.96
EPS (ttm) 5.51
Insider Own 0.67%
Shs Outstand 69.91M
Perf Week 1.16%
Market Cap 16.59B
Forward P/E 61.35
EPS next Y 3.86
Insider Trans -6.55%
Shs Float 69.64M
Perf Month 27.33%
Income 395.30M
PEG 2.88
EPS next Q 0.79
Inst Own 100.66%
Short Float 4.19%
Perf Quarter 15.91%
Sales 1.87B
P/S 8.86
EPS this Y 2.24%
Inst Trans -0.62%
Short Ratio 3.91
Perf Half Y 41.97%
Book/sh 14.24
P/B 16.61
EPS next Y 28.30%
ROA 15.01%
Short Interest 2.92M
Perf Year 43.61%
Cash/sh 11.71
P/C 20.21
EPS next 5Y 14.90%
ROE 50.93%
52W Range 125.82 - 243.98
Perf YTD 9.03%
Dividend Est. -
P/FCF 86.85
EPS past 5Y 122.47%
ROI 16.76%
52W High -3.03%
Beta 1.21
Dividend TTM -
Quick Ratio 2.68
Sales past 5Y 24.75%
Gross Margin 69.59%
52W Low 88.03%
ATR (14) 7.86
Dividend Ex-Date -
Current Ratio 3.56
EPS Y/Y TTM 525.48%
Oper. Margin 14.56%
RSI (14) 74.13
Volatility 2.93% 3.72%
Employees 3000
Debt/Eq 1.40
Sales Y/Y TTM 27.82%
Profit Margin 21.11%
Recom 1.52
Target Price 239.05
Option/Short Yes / Yes
LT Debt/Eq 1.36
EPS Q/Q 565.31%
Payout 0.00%
Rel Volume 1.80
Prev Close 237.68
Sales Surprise 0.10%
EPS Surprise 359.46%
Sales Q/Q 23.20%
Earnings Aug 08 AMC
Avg Volume 746.92K
Price 236.58
SMA20 10.36%
SMA50 17.00%
SMA200 24.07%
Trades
Volume 1,347,054
Change -0.46%
Date
Action
Analyst
Rating Change
Price Target Change
May-30-24 Initiated
Redburn Atlantic
Buy
$235
May-07-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$200
Dec-21-23 Upgrade
Robert W. Baird
Neutral → Outperform
$180 → $238
Dec-04-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$185 → $234
Oct-02-23 Upgrade
Jefferies
Hold → Buy
$260 → $240
Aug-21-23 Upgrade
Citigroup
Neutral → Buy
$273 → $265
Aug-21-23 Downgrade
Robert W. Baird
Outperform → Neutral
$320 → $219
May-30-23 Resumed
Morgan Stanley
Equal-Weight
$343
Jan-26-23 Initiated
Wolfe Research
Peer Perform
Nov-04-22 Upgrade
Piper Sandler
Neutral → Overweight
$235 → $340
Oct-18-22 Initiated
Barclays
Equal Weight
$238
Oct-12-22 Initiated
Jefferies
Hold
$260
Jul-11-22 Downgrade
Citigroup
Buy → Neutral
$310 → $250
Mar-02-22 Resumed
BofA Securities
Buy
$300
Feb-03-22 Upgrade
BTIG Research
Neutral → Buy
$320
Feb-02-22 Upgrade
UBS
Neutral → Buy
$325
Jan-31-22 Upgrade
Oppenheimer
Perform → Outperform
$300 → $275
Jul-21-21 Resumed
Cowen
Outperform
$285 → $310
May-25-21 Initiated
Barclays
Overweight
$300
Apr-01-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
$275 → $320
Show Previous Ratings
Sep-12-24 01:01PM
Sep-07-24 01:16AM
Sep-05-24 07:22PM
Sep-04-24 05:00PM
Aug-30-24 10:35AM
07:20AM
Loading…
07:20AM
01:46AM
Aug-28-24 05:25PM
Aug-27-24 05:36PM
12:48PM
11:32AM
10:08AM
08:23AM
Aug-26-24 04:20PM
01:37PM
05:25PM
Loading…
Aug-20-24 05:25PM
05:21PM
12:11PM
06:00AM
Aug-16-24 08:57PM
Aug-14-24 03:00AM
Aug-10-24 01:04AM
Aug-09-24 05:34PM
(Morningstar Research) -8.81%
05:31PM
05:15PM
01:19PM
12:49PM
10:48AM
09:24AM
Aug-08-24 08:07PM
05:30PM
Loading…
05:30PM
05:15PM
04:07PM
(Associated Press Finance)
04:01PM
Aug-07-24 09:02AM
Aug-05-24 09:16AM
Aug-01-24 10:01AM
Jul-26-24 09:37AM
(The Wall Street Journal)
06:00AM
Jul-18-24 12:00PM
Jul-16-24 08:45AM
Jul-08-24 06:00AM
Jun-25-24 02:32PM
Jun-24-24 04:08PM
08:36AM
08:13AM
07:13AM
Jun-21-24 06:30PM
10:59AM
08:33AM
Jun-20-24 06:05AM
06:00AM
Jun-19-24 06:02AM
Jun-17-24 07:01PM
Jun-13-24 09:24AM
Jun-11-24 07:00PM
Jun-06-24 06:19AM
May-30-24 09:59AM
May-28-24 06:00AM
May-23-24 09:50AM
May-22-24 09:45AM
May-19-24 02:08PM
May-16-24 07:42AM
May-14-24 04:47PM
04:44PM
03:58PM
11:19AM
May-13-24 10:48AM
May-10-24 04:55PM
03:25PM
12:24PM
09:43AM
09:24AM
08:10AM
08:00AM
07:49AM
May-09-24 08:57PM
05:30PM
04:30PM
04:11PM
(Associated Press Finance)
04:01PM
10:16AM
May-07-24 06:00AM
May-06-24 09:16AM
May-02-24 06:15PM
09:50AM
Apr-28-24 05:50PM
Apr-26-24 06:15PM
Apr-24-24 08:42AM
Apr-15-24 09:45AM
Apr-12-24 12:10PM
Apr-10-24 06:15PM
Apr-03-24 06:00AM
Apr-02-24 09:45AM
Mar-28-24 09:55AM
Mar-26-24 05:10AM
Mar-21-24 09:17AM
06:40AM
Mar-20-24 08:11AM
06:00AM
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hopfield Jessica Director Sep 11 '24 Option Exercise 29.87 7,628 227,848 34,545 Sep 12 04:07 PM Hopfield Jessica Director Sep 11 '24 Sale 225.26 7,628 1,718,283 26,917 Sep 12 04:07 PM Scannell Timothy J Director Sep 10 '24 Sale 225.84 5,000 1,129,200 30,586 Sep 11 04:13 PM Hopfield Jessica Director Sep 11 '24 Proposed Sale 225.26 7,628 1,718,283 Sep 11 03:40 PM Field Mark N SVP & Chief Technology Officer Sep 09 '24 Sale 220.87 1,383 305,463 9,761 Sep 10 04:16 PM Budden Lauren Group VP, CAO and Controller Sep 09 '24 Sale 221.41 1,506 333,443 6,609 Sep 10 04:15 PM Scannell Timothy J Director Sep 10 '24 Proposed Sale 225.84 5,000 1,129,210 Sep 10 02:27 PM Field Mark N Officer Sep 09 '24 Proposed Sale 220.87 1,383 305,465 Sep 09 04:50 PM Budden Lauren Officer Sep 09 '24 Proposed Sale 221.41 1,506 333,436 Sep 09 01:20 PM Singh Prem SVP, Global Operations Aug 30 '24 Sale 202.27 1,824 368,940 3,656 Sep 03 04:30 PM Singh Prem Officer Aug 30 '24 Proposed Sale 202.27 1,824 368,938 Aug 30 03:22 PM Chadwick Ana Maria EVP, CFO & Treasurer Aug 29 '24 Buy 206.00 100 20,600 13,314 Aug 29 04:17 PM Field Mark N SVP & Chief Technology Officer Aug 28 '24 Sale 203.00 1,387 281,561 11,347 Aug 29 04:14 PM Field Mark N Officer Aug 28 '24 Proposed Sale 203.00 1,387 281,561 Aug 28 04:02 PM Field Mark N SVP & Chief Technology Officer Jun 14 '24 Sale 199.96 1,500 299,940 12,875 Jun 17 04:11 PM Scannell Timothy J Director Jun 10 '24 Sale 190.51 7,000 1,333,570 35,586 Jun 11 04:12 PM Field Mark N SVP & Chief Technology Officer Jun 10 '24 Sale 190.43 2,131 405,806 14,375 Jun 11 04:11 PM BORIO LUCIANA Director Jun 04 '24 Sale 182.58 360 65,729 3,298 Jun 05 04:13 PM Scannell Timothy J Director May 28 '24 Option Exercise 32.33 18,267 590,595 45,886 May 29 04:04 PM Scannell Timothy J Director May 28 '24 Sale 180.90 3,300 596,970 42,586 May 29 04:04 PM Petrovic Shacey Director Feb 28 '24 Option Exercise 92.11 11,609 1,069,305 14,176 Feb 29 04:37 PM Petrovic Shacey Director Feb 28 '24 Sale 162.92 11,609 1,891,338 2,567 Feb 29 04:37 PM BORIO LUCIANA Director Dec 15 '23 Sale 207.08 72 14,910 2,278 Dec 18 04:01 PM Petrovic Shacey Director Nov 13 '23 Option Exercise 81.69 20,000 1,633,733 22,567 Nov 14 04:04 PM Petrovic Shacey Director Nov 13 '23 Sale 164.33 20,000 3,286,600 2,567 Nov 14 04:04 PM Petrovic Shacey Director Nov 13 '23 Sale 165.02 15,000 2,475,300 0 Nov 14 04:04 PM
Index RUT
P/E -
EPS (ttm) -2.36
Insider Own 0.94%
Shs Outstand 81.77M
Perf Week -4.56%
Market Cap 310.95M
Forward P/E -
EPS next Y -2.75
Insider Trans -1.35%
Shs Float 81.70M
Perf Month -7.60%
Income -193.45M
PEG -
EPS next Q -0.78
Inst Own 69.52%
Short Float 22.04%
Perf Quarter -26.22%
Sales 67.03M
P/S 4.64
EPS this Y -44.10%
Inst Trans 2.32%
Short Ratio 9.74
Perf Half Y -51.85%
Book/sh 2.81
P/B 1.34
EPS next Y 5.67%
ROA -41.75%
Short Interest 18.01M
Perf Year -52.58%
Cash/sh 3.38
P/C 1.11
EPS next 5Y 1.70%
ROE -61.23%
52W Range 3.40 - 11.69
Perf YTD -62.78%
Dividend Est. -
P/FCF -
EPS past 5Y 2.88%
ROI -76.61%
52W High -67.75%
Beta 1.99
Dividend TTM -
Quick Ratio 3.85
Sales past 5Y 101.57%
Gross Margin 91.33%
52W Low 10.88%
ATR (14) 0.23
Dividend Ex-Date -
Current Ratio 3.85
EPS Y/Y TTM 20.53%
Oper. Margin -317.78%
RSI (14) 44.30
Volatility 5.82% 5.59%
Employees 265
Debt/Eq 0.17
Sales Y/Y TTM 247.03%
Profit Margin -288.59%
Recom 2.05
Target Price 13.80
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -45.51%
Payout -
Rel Volume 3.12
Prev Close 3.91
Sales Surprise -89.27%
EPS Surprise -16.48%
Sales Q/Q -82.23%
Earnings Aug 07 BMO
Avg Volume 1.85M
Price 3.77
SMA20 0.75%
SMA50 -14.58%
SMA200 -42.75%
Trades
Volume 5,769,271
Change -3.58%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Upgrade
BofA Securities
Neutral → Buy
$13 → $15
May-09-24 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$7
Oct-24-23 Upgrade
Citigroup
Neutral → Buy
$11
Oct-18-23 Upgrade
JP Morgan
Underweight → Neutral
$8
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-29-23 Upgrade
Stifel
Hold → Buy
$9 → $17
Jun-12-23 Upgrade
Raymond James
Mkt Perform → Outperform
$17
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$15
Dec-13-22 Initiated
Citigroup
Neutral
$11
Dec-06-22 Resumed
Credit Suisse
Neutral
$13
Nov-18-22 Downgrade
Oppenheimer
Outperform → Perform
$28 → $12
Nov-18-22 Downgrade
Credit Suisse
Outperform → Neutral
$25 → $13
Sep-29-22 Initiated
BofA Securities
Neutral
$18
Oct-19-21 Initiated
SVB Leerink
Mkt Perform
$41
Sep-24-21 Initiated
Stifel
Hold
$65
Sep-10-21 Upgrade
Oppenheimer
Perform → Outperform
$42 → $80
Aug-09-21 Upgrade
Truist
Hold → Buy
$45 → $80
Aug-05-21 Upgrade
Evercore ISI
Underperform → Outperform
$20 → $60
Jun-04-21 Resumed
Robert W. Baird
Outperform
$44
May-04-21 Initiated
RBC Capital Mkts
Sector Perform
$40
Show Previous Ratings
Sep-06-24 11:31AM
Aug-28-24 09:00AM
Aug-08-24 09:33AM
03:39AM
(Thomson Reuters StreetEvents)
Aug-07-24 08:05AM
07:07AM
Loading…
07:07AM
(Associated Press Finance)
07:00AM
Jul-31-24 07:00AM
Jul-17-24 11:30AM
Jul-09-24 07:59AM
Jul-08-24 09:00AM
Jun-29-24 08:40PM
06:30PM
Jun-27-24 09:04AM
Jun-26-24 09:33PM
04:36PM
Loading…
04:36PM
Jun-25-24 08:00AM
Jun-17-24 08:13AM
Jun-14-24 03:01AM
03:00AM
Jun-07-24 11:30AM
May-22-24 07:05PM
May-14-24 07:01PM
04:27PM
10:00AM
May-10-24 06:00AM
May-09-24 03:38PM
01:12PM
12:40PM
11:33AM
08:00AM
Loading…
08:00AM
May-08-24 10:33PM
(Thomson Reuters StreetEvents) -11.36%
11:55AM
08:25AM
07:29AM
(Associated Press Finance)
07:00AM
May-02-24 07:00AM
May-01-24 10:46AM
08:00AM
Apr-29-24 10:26AM
Apr-26-24 10:00AM
Apr-22-24 04:31PM
Mar-29-24 11:30AM
Mar-07-24 03:31AM
Mar-05-24 11:52PM
Mar-04-24 10:30AM
Mar-02-24 09:49PM
Feb-29-24 11:26AM
08:42AM
Feb-28-24 11:15PM
(Thomson Reuters StreetEvents) +24.94%
08:10AM
07:35AM
07:08AM
(Associated Press Finance)
07:00AM
Feb-21-24 07:00AM
Feb-19-24 09:55AM
Feb-10-24 05:09PM
Feb-06-24 12:00PM
Jan-31-24 09:00AM
Jan-28-24 08:45AM
Jan-21-24 09:37AM
Jan-17-24 12:04PM
Jan-15-24 05:19AM
Jan-11-24 04:38PM
Jan-08-24 08:15AM
07:45AM
Jan-03-24 07:00AM
Jan-02-24 10:15AM
Dec-23-23 08:02AM
Dec-14-23 08:32AM
06:30AM
Dec-13-23 05:12PM
04:06PM
12:30PM
09:00AM
Dec-11-23 01:22PM
12:00PM
Dec-10-23 11:59AM
Dec-05-23 07:00AM
Nov-29-23 02:28PM
Nov-22-23 06:30AM
Nov-20-23 05:43PM
(InvestorPlace) +10.84%
-6.64%
05:36AM
Nov-16-23 03:25PM
Nov-09-23 03:37PM
Nov-06-23 09:00AM
Nov-05-23 05:51PM
Nov-03-23 08:45AM
08:34AM
07:17AM
(Associated Press Finance)
07:00AM
Nov-02-23 09:12AM
Oct-30-23 03:46PM
Oct-27-23 07:00AM
Oct-24-23 09:51AM
01:53AM
Oct-18-23 11:05AM
09:52AM
09:30AM
Oct-17-23 11:47AM
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mei Baisong EVP, CHIEF MEDICAL OFFICER Sep 04 '24 Sale 3.42 518 1,774 133,895 Sep 06 04:20 PM O'Neill Gilmore Neil CEO Sep 04 '24 Sale 3.42 1,555 5,325 313,724 Sep 06 04:18 PM O'Neill Gilmore Neil Officer Sep 03 '24 Proposed Sale 3.92 3,000 11,760 Aug 29 04:19 PM Mei Baisong Officer Sep 03 '24 Proposed Sale 3.92 1,000 3,920 Aug 29 04:17 PM Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Jul 25 '24 Sale 5.42 11,886 64,370 73,136 Jul 26 05:02 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jul 19 '24 Sale 5.21 6,619 34,456 134,413 Jul 22 05:01 PM O'Neill Gilmore Neil CEO Jun 04 '24 Sale 5.50 12,191 66,997 315,279 Jun 06 04:17 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jun 04 '24 Sale 5.50 511 2,808 141,032 Jun 06 04:16 PM Lucera Erick EVP, CHIEF FINANCIAL OFFICER May 20 '24 Sale 5.61 22,337 125,404 116,829 May 22 04:30 PM Hopfield Jessica Director May 13 '24 Buy 5.64 45,000 253,868 67,700 May 14 04:17 PM O'Neill Gilmore Neil CEO Mar 05 '24 Sale 9.42 77,824 732,884 327,470 Mar 05 08:00 PM Mei Baisong SVP, CHIEF MEDICAL OFFICER Mar 04 '24 Sale 9.42 20,327 191,425 141,543 Mar 05 07:54 PM Eaton Bruce EVP, CBO AND CTO Dec 05 '23 Sale 10.90 103 1,122 74,791 Dec 07 04:30 PM Eaton Bruce EVP, CBO AND CTO Nov 14 '23 Sale 8.21 695 5,706 74,894 Nov 16 04:30 PM Eaton Bruce EVP, CBO AND CTO Nov 07 '23 Sale 8.40 139 1,168 75,589 Nov 09 04:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite